Revolution Medicines, Inc.
RVMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $206 | $188 |
| Gross Profit | $0 | $0 | -$206 | -$188 |
| % Margin | – | – | – | – |
| R&D Expenses | $263 | $224 | $206 | $188 |
| G&A Expenses | $53 | $41 | $35 | $28 |
| SG&A Expenses | $53 | $41 | $35 | $28 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$206 | -$188 |
| Operating Expenses | $315 | $265 | $35 | $28 |
| Operating Income | -$315 | -$265 | -$241 | -$216 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10 | $17 | $27 | $21 |
| Pre-Tax Income | -$305 | -$248 | -$213 | -$195 |
| Tax Expense | $0 | $0 | $0 | -$1 |
| Net Income | -$305 | -$248 | -$213 | -$195 |
| % Margin | – | – | – | – |
| EPS | -1.61 | -1.31 | -1.13 | -1.13 |
| % Growth | -22.9% | -15.9% | 0% | – |
| EPS Diluted | -1.61 | -1.31 | -1.13 | -1.13 |
| Weighted Avg Shares Out | 189 | 188 | 188 | 168 |
| Weighted Avg Shares Out Dil | 189 | 188 | 188 | 168 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11 | $22 | $25 | $21 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $4 | $4 | $3 |
| EBITDA | -$302 | -$261 | -$237 | -$213 |
| % Margin | – | – | – | – |